Histology of Luminal Breast Cancer

被引:21
|
作者
Erber, Ramona [1 ]
Hartmann, Arndt [1 ]
机构
[1] Friedrich Alexander Univ Erlangen Nurnberg FAU, Comprehens Canc Ctr Erlangen EMN, Univ Hosp Erlangen, Inst Pathol, Erlangen, Germany
关键词
Luminal A; Luminal B; Breast cancer; Estrogen receptor; Histological subtypes; INVASIVE CRIBRIFORM CARCINOMA; LOBULAR CARCINOMA; MICROPAPILLARY CARCINOMA; SEBACEOUS CARCINOMA; DUCTAL CARCINOMA; IN-SITU; CLINICOPATHOLOGICAL FEATURES; TUBULOLOBULAR CARCINOMA; MUCINOUS CARCINOMA; APOCRINE CARCINOMA;
D O I
10.1159/000509025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background:Invasive breast cancer (IBC) can be categorized into prognostic and predictive molecular subtypes (including luminal breast cancer) using gene expression profiling. Luminal IBC comprises a variety of histological subtypes with varying clinical and pathological features.Summary:IBC of no special subtype is the most common histological subtype in general and likewise within luminal IBC. Classical invasive lobular breast cancer, typically clustering into luminal subgroup, is characterized by discohesive growth and loss of E-cadherin expression. Infrequent, morphologically distinct luminal IBC subtypes are tubular, invasive cribriform, mucinous, and invasive micropapillary carcinomas. Breast carcinoma with apocrine differentiation, with characteristic expression of androgen receptor (AR), often clusters into the luminal AR category. Rarely, neuroendocrine neoplasms of the breast can be seen. IBC of the male breast usually matches with the luminal subtype.Key Messages:Independently from histological subtypes, invasive breast cancer (IBC) can be divided into molecular subtypes based on mRNA gene expression levels. Using this molecular subtyping, risk scores based on gene expression profiling (established for hormone receptor-positive, HER2-negative IBC), grading, and Ki-67 index, prognosis of patients with luminal breast cancer and response to chemotherapy can be predicted. In routine diagnostics, the expression of estrogen receptor (ER) and progesterone receptor (PR), HER2 status, and the proliferation rate (Ki-67) are used to determine a surrogate (molecular-like) subtype. Within luminal(-like) IBC, no special subtype and invasive lobular breast carcinoma are the most common histological subtypes. Other rare histological subtypes (e.g., tubular carcinoma) should be recognized due to their distinct clinical and pathological features.
引用
收藏
页码:327 / 336
页数:10
相关论文
共 50 条
  • [21] The Contribution of Glutamine Metabolism in Luminal Breast Cancer
    Erkan, B.
    MacIntyre, S.
    Brown, C.
    Fakroun, A.
    Mongan, N.
    Ellis, I
    Rakha, E.
    Green, A.
    JOURNAL OF PATHOLOGY, 2023, 261 (SUPPL1): : S23 - S23
  • [22] Role of epigenetic modifications in luminal breast cancer
    Abdel-Hafiz, Hany A.
    Horwitz, Kathryn B.
    EPIGENOMICS, 2015, 7 (05) : 847 - 862
  • [23] A model of tumor dormancy in Luminal A breast cancer
    Sansone, Pasquale
    Shapiro, Lauren
    Chang, Qing
    Berishaj, Malian
    Bromberg, Jaqueline
    CANCER RESEARCH, 2011, 71
  • [24] Luminal breast cancer: from biology to treatment
    Ignatiadis, Michail
    Sotiriou, Christos
    NATURE REVIEWS CLINICAL ONCOLOGY, 2013, 10 (09) : 494 - 506
  • [25] Basal markers and prognosis in luminal breast cancer
    Monica J. Engstrøm
    Marit Valla
    Anna M. Bofin
    Breast Cancer Research and Treatment, 2017, 163 : 207 - 217
  • [26] Outcome of special types of luminal breast cancer
    Colleoni, M.
    Rotmensz, N.
    Maisonneuve, P.
    Mastropasqua, M. G.
    Luini, A.
    Veronesi, P.
    Intra, M.
    Montagna, E.
    Cancello, G.
    Cardillo, A.
    Mazza, M.
    Perri, G.
    Iorfida, M.
    Pruneri, G.
    Goldhirsch, A.
    Viale, G.
    ANNALS OF ONCOLOGY, 2012, 23 (06) : 1428 - +
  • [27] Circulating Microrna Biomarkers for Luminal a Breast Cancer
    Martyn, L. M.
    McDermott, A. M.
    Miller, N.
    Kerin, M. J.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2013, 182 : S331 - S331
  • [28] BREAST CANCER Luminal cells with an identity crisis
    Alderton, Gemma K.
    NATURE REVIEWS CANCER, 2011, 11 (03) : 158 - 158
  • [29] Basal markers and prognosis in luminal breast cancer
    Engstrom, Monica J.
    Valla, Marit
    Bofin, Anna M.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 163 (02) : 207 - 217
  • [30] The molecular profile of luminal B breast cancer
    Creighton, Chad J.
    BIOLOGICS-TARGETS & THERAPY, 2012, 6 : 289 - 297